MABEL Fund

Declare the past, diagnose the present, foretell the future

~ Hippocrates

Over the last years, the research groups Clinical Pharmacology and Pharmacotherapy and Therapeutic and Diagnostic Antibodies of the Department of Pharmaceutical & Pharmacological sciences of KU Leuven (Leuven, Belgium) in collaboration with the Erasmus University Medical Center (Rotterdam, the Netherlands) have established a research programme exploring the market environment of biologics and biosimilars following loss of exclusivity, called MABEL.

Situated in Belgium, in the heart of Western Europe, KU Leuven has been a centre of learning for nearly six centuries. Today, it is Belgium's largest university and, founded in 1425, one of the oldest and most renowned universities in Europe. As a leading European research university and co-founder of the League of European Research Universities, KU Leuven offers a wide variety of international master’s programmes, all supported by high-quality, innovative, interdisciplinary research.

The Department of Pharmaceutical and Pharmacological Sciences at KU Leuven is an internationally recognized research center in all aspects of therapeutics and diagnostics from target to market. It covers expertise in research and teaching spanning the entire drug discovery and development process, carries out studies on the use of medicinal products in society and guides practitioners in the field.

Erasmus MC excels in different areas of research, the study of basic and clinical domains, as well as public health and prevention. Research of the Erasmus MC is at the heart of society, resulting in innovation, quality and increased efficiency in patient care.